摘要
目的评价伊立替康联合替吉奥三线治疗进展期胃癌的有效性与安全性。方法 45例进展期胃癌患者,男29例,女16例,既往接受过含奥沙利铂、顺铂、紫杉类、氟尿嘧啶类药物的化疗,ECOG评分0～2分,予伊立替康(CPT-11)140 mg·m-2,d1;替吉奥胶囊60 mg·m-2·d-1,分两次口服,d1～14,28 d为一个周期,化疗2周期后按RECIST1.1标准评价近期疗效,每周期均按NCI-CTCAE3.0评价不良反应。结果 4例患者因不良反应不能耐受仅接受1个周期治疗未能评价疗效,41例可评价患者中CR:2.44%(1/41),PR:21.95%(9/41),SD:46.34%(19/41),PD:29.27%(12/41),客观缓解率(CR+PR)24.39%(10/41),疾病控制率(CR+PR+SD)70.73%(29/41)。骨髓抑制是剂量限制性毒性,其他主要不良反应为腹泻、乏力、纳差、恶心等。结论伊立替康联合替吉奥胶囊三线治疗进展期胃癌,近期缓解较好,给药方便,不良反应可耐受,值得临床进一步探索。
Objective To evaluate the effectiveness and safety of CPT-11 combined with S-1 in third line treatment of advanced gastric cancer.Methods Totally 45 patients with advanced gastric cancer comprised of 29 male and 16 females and treated with oxaliplatin,cisplatin,taxane,fluorouracil before and the score of ECOG was 0～2 were treated with CPT-11,140 mg·m-2 on day 1 and S-160 mg·m-2·d-1,twice a day per oral from day 1 to day 14.One treatment cycle covered 28 days.The short-term effects of combination treatment were assessed after 2 cycles according to RECIST1.1 standard;meanwhile the side effects were assessed per cycle according to NCI-CTCAE3.0.Results Four patients were not assessed for efficacy because of intolerance and only one treatment cycle.In other 41 patients,complete remission ratio（CR） was 2.44%（1/41）,partial response ratio（PR）21.95%（9/41）,stable disease（SD）46.34%（19/41）,progressive disease（PD）29.27%（12/41）,objective response rate（CR＋PR）24.39%（10/41）,disease control rate（CR＋PR＋SD） 70.73%（29/41）.The myelosuppression was dose-limited toxicity,and the other side effects were diarrhea,fatigue,anorexia,and nausea etc.Conclusions CPT-11 combined with S-1 in 1ine-3 treatment of patients with advanced gastric cancer can get better short-term efficacy with convenient medication and tolerated side effects.This combination strategy thus deserves further examination in clinics.
出处
《安徽医药》
CAS
2012年第12期1859-1861,共3页
Anhui Medical and Pharmaceutical Journal
